This report describes and explains the Abrysvo or Arexvy market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global Abrysvo or Arexvy market reached a value of nearly $1.54 billion in 2024, having declined at a compound annual growth rate (CAGR) of -39.36% since 2019. The market is expected to decline from $1.54 billion in 2024 to $1.37 billion in 2029 at a rate of -2.24%. The market is then expected to grow at a CAGR of 4.97% from 2029 and reach $1.75 billion in 2034.
Growth in the historic period resulted from supportive government health policies, surge in respiratory infections, rise in seasonal vaccination demand and rising hospitalizations due to RSV. Factors that negatively affected growth in the historic period were vaccine hesitancy and side effect and awareness and perception barriers.
Going forward, increasing aging population, rising public health funding, public awareness campaigns and shift towards preventative healthcare will drive growth. Factor that could hinder the growth of the Abrysvo or Arexvy market in the future include were Impact Of trade war and tariff, uneven reimbursement policies and stringent regulatory requirements.
North America was the largest region in the Abrysvo or Arexvy market, accounting for 85.46% or $1.32 billion of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the Abrysvo or Arexvy market will be Africa and Asia Pacific where growth will be at CAGRs of 45.65% and 23.93% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 22.73% and 21.00% respectively.
The global Abrysvo or Arexvy market is highly concentrated, with two large players operating in the market. The major 2 competitors in the market made up to 100% of the total market in 2024. GlaxoSmithKline (GSK) Plc was the largest competitor with a 51.15% share of the market, followed by Pfizer Inc. with 48.85%.
The Abrysvo or Arexvy market is segmented by clinical indication into respiratory syncytial virus (RSV) prevention and infant protection. The respiratory syncytial virus (RSV) prevention market was the largest segment of the Abrysvo or Arexvy market segmented by clinical indication, accounting for 79.85% or $1.23 billion of the total in 2024.
The Abrysvo or Arexvy market is segmented by age group into adults (18-59 years), older adults (60+ years) and pregnant individuals (32-36 weeks of gestation). The older adults (60+ years) market was the largest segment of the Abrysvo or Arexvy market segmented by age group, accounting for 74.93% or $1.15 billion of the total in 2024.
The Abrysvo or Arexvy market is segmented by distribution channel into hospitals and healthcare providers, government / public health programs and other distributional channels. The hospitals and healthcare providers market was the largest segment of the Abrysvo or Arexvy market segmented by distribution channel, accounting for 58.79% or $908.73 million of the total in 2024.
Market-trend-based strategies for the Abrysvo or Arexvy market include focusing on maternal immunization strategies to protect infants during the first six months of life, using on expanding their preventive solutions across different adult populations and using on the development of preventive solutions tailored to high-risk populations, such as older adults.
Player-adopted strategies in the Abrysvo or Arexvy market include focus on expanding its business capabilities through diversification.
To take advantage of the opportunities, the analyst recommends the abrysvo or arexvy market companies to focus on expanding maternal immunization and global access strategies, focus on expanding vaccine indications and adult population coverage, focus on advancing preventive solutions for high-risk adult populations, focus on expanding the respiratory syncytial virus (RSV) prevention segment, focus on expanding the older adults (60+ years) segment, expand in emerging markets, focus on strengthening multi-channel distribution networks, focus on value-based pricing to strengthen market position, strengthening abrysvo’s promotional strategy for market penetration and awareness growth, enhancing arexvy’s promotional approach for competitive differentiation and uptake optimization and focus on hospitals and healthcare providers to drive sustainable growth.
The global Abrysvo or Arexvy market reached a value of nearly $1.54 billion in 2024, having declined at a compound annual growth rate (CAGR) of -39.36% since 2019. The market is expected to decline from $1.54 billion in 2024 to $1.37 billion in 2029 at a rate of -2.24%. The market is then expected to grow at a CAGR of 4.97% from 2029 and reach $1.75 billion in 2034.
Growth in the historic period resulted from supportive government health policies, surge in respiratory infections, rise in seasonal vaccination demand and rising hospitalizations due to RSV. Factors that negatively affected growth in the historic period were vaccine hesitancy and side effect and awareness and perception barriers.
Going forward, increasing aging population, rising public health funding, public awareness campaigns and shift towards preventative healthcare will drive growth. Factor that could hinder the growth of the Abrysvo or Arexvy market in the future include were Impact Of trade war and tariff, uneven reimbursement policies and stringent regulatory requirements.
North America was the largest region in the Abrysvo or Arexvy market, accounting for 85.46% or $1.32 billion of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the Abrysvo or Arexvy market will be Africa and Asia Pacific where growth will be at CAGRs of 45.65% and 23.93% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 22.73% and 21.00% respectively.
The global Abrysvo or Arexvy market is highly concentrated, with two large players operating in the market. The major 2 competitors in the market made up to 100% of the total market in 2024. GlaxoSmithKline (GSK) Plc was the largest competitor with a 51.15% share of the market, followed by Pfizer Inc. with 48.85%.
The Abrysvo or Arexvy market is segmented by clinical indication into respiratory syncytial virus (RSV) prevention and infant protection. The respiratory syncytial virus (RSV) prevention market was the largest segment of the Abrysvo or Arexvy market segmented by clinical indication, accounting for 79.85% or $1.23 billion of the total in 2024.
The Abrysvo or Arexvy market is segmented by age group into adults (18-59 years), older adults (60+ years) and pregnant individuals (32-36 weeks of gestation). The older adults (60+ years) market was the largest segment of the Abrysvo or Arexvy market segmented by age group, accounting for 74.93% or $1.15 billion of the total in 2024.
The Abrysvo or Arexvy market is segmented by distribution channel into hospitals and healthcare providers, government / public health programs and other distributional channels. The hospitals and healthcare providers market was the largest segment of the Abrysvo or Arexvy market segmented by distribution channel, accounting for 58.79% or $908.73 million of the total in 2024.
Market-trend-based strategies for the Abrysvo or Arexvy market include focusing on maternal immunization strategies to protect infants during the first six months of life, using on expanding their preventive solutions across different adult populations and using on the development of preventive solutions tailored to high-risk populations, such as older adults.
Player-adopted strategies in the Abrysvo or Arexvy market include focus on expanding its business capabilities through diversification.
To take advantage of the opportunities, the analyst recommends the abrysvo or arexvy market companies to focus on expanding maternal immunization and global access strategies, focus on expanding vaccine indications and adult population coverage, focus on advancing preventive solutions for high-risk adult populations, focus on expanding the respiratory syncytial virus (RSV) prevention segment, focus on expanding the older adults (60+ years) segment, expand in emerging markets, focus on strengthening multi-channel distribution networks, focus on value-based pricing to strengthen market position, strengthening abrysvo’s promotional strategy for market penetration and awareness growth, enhancing arexvy’s promotional approach for competitive differentiation and uptake optimization and focus on hospitals and healthcare providers to drive sustainable growth.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global Abrysvo or Arexvy Growth Analysis and Strategic Analysis Framework
9 Global Abrysvo or Arexvy Market Segmentation
10 Abrysvo or Arexvy Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape and Company Profiles
21 Opportunities and Strategies
22 Abrysvo or Arexvy Market, Conclusions and Recommendations
23 Appendix
Executive Summary
Abrysvo or Arexvy Global Market Opportunities and Strategies to 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global abrysvo or arexvy market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 11 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for abrysvo or arexvy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The abrysvo or arexvy market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider abrysvo or arexvy market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by age group and by end user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework - Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM)..
- Regional and Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by age group and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
- Competitive Dashboard Briefs on competitive dashboard of major players.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report.This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments - Information on recent developments in the market covered in the report.
- Market Opportinities and Strategies - Contains information on growth opportunities across countries, segments and strategies to be followed in those markets.It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes recommendations for abrysvo or arexvy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
2) By Age Group: Adults (18-59 Years); Older Adults (60+ Years); Pregnant Individuals (32-36 Weeks of Gestation)
3) By Distribution Channel: Hospitals and Healthcare Providers; Government / Public Health Programs; Other Distributional Channels
Companies Mentioned: GlaxoSmithKline (GSK) Plc; Pfizer Inc.
Countries: China; Australia; India; Japan; South Korea; USA; Canada; France; Germany; UK
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; abrysvo or arexvy indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
The companies profiled in this Abrysvo Or Arexvy market report include:- GlaxoSmithKline (GSK) Plc
- Pfizer Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 246 |
| Published | December 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.54 Billion |
| Forecasted Market Value ( USD | $ 1.75 Billion |
| Compound Annual Growth Rate | 1.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 3 |
